These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 29536856)

  • 1. Bioresorbable polymer drug-eluting stents.
    Alkhalil M
    Lancet; 2018 Mar; 391(10124):936. PubMed ID: 29536856
    [No Abstract]   [Full Text] [Related]  

  • 2. Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial.
    Kandzari DE; Mauri L; Koolen JJ; Massaro JM; Doros G; Garcia-Garcia HM; Bennett J; Roguin A; Gharib EG; Cutlip DE; Waksman R;
    Lancet; 2017 Oct; 390(10105):1843-1852. PubMed ID: 28851504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioresorbable polymer drug-eluting stents.
    Shah R
    Lancet; 2018 Mar; 391(10124):935-936. PubMed ID: 29536854
    [No Abstract]   [Full Text] [Related]  

  • 4. Bioresorbable polymer drug-eluting stents - Authors' reply.
    Kandzari DE; Mauri L; Koolen JJ; Doros G; Waksman R
    Lancet; 2018 Mar; 391(10124):936-937. PubMed ID: 29536855
    [No Abstract]   [Full Text] [Related]  

  • 5. Biodegradable-Polymer Biolimus-Eluting Stents versus Durable-Polymer Everolimus-Eluting Stents at One-Year Follow-Up: A Registry-Based Cohort Study.
    Parsa E; Saroukhani S; Majlessi F; Poorhosseini H; Lofti-Tokaldany M; Jalali A; Salarifar M; Nematipour E; Alidoosti M; Aghajani H; Amirzadegan A; Kassaian SE
    Tex Heart Inst J; 2016 Apr; 43(2):126-30. PubMed ID: 27127426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coronary bifurcations: still the touchstone of drug-eluting stents and bioresorbable vascular scaffolds?
    von Birgelen C; van Houwelingen KG; Lam MK
    Rev Esp Cardiol (Engl Ed); 2014 Oct; 67(10):787-9. PubMed ID: 25262123
    [No Abstract]   [Full Text] [Related]  

  • 7. Biodegradable polymer drug-eluting stents: caveat emptor.
    Byrne RA; Schuster T
    Lancet; 2017 Oct; 390(10105):1814-1816. PubMed ID: 29082870
    [No Abstract]   [Full Text] [Related]  

  • 8. Biodegradable-polymer drug-eluting stents: back to the future?
    Cassese S; Xhepa E; Kastrati A
    Heart; 2017 Jan; 103(2):91-92. PubMed ID: 27628493
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety and efficacy profile of bioresorbable-polylactide-polymer-biolimus-A9-eluting stents versus durable-polymer-everolimus- and zotarolimus-eluting stents in patients with acute coronary syndrome.
    Jaguszewski M; Dörig M; Frangieh AH; Ghadri JR; Cammann VL; Diekmann J; Napp LC; D'Ascenzo F; Imori Y; Obeid S; Maier W; Lüscher TF; Templin C
    Catheter Cardiovasc Interv; 2016 Nov; 88(6):E173-E182. PubMed ID: 27377554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of sirolimus eluting stent with bioresorbable polymer to everolimus eluting stent with permanent polymer in bifurcation lesions: Results from CENTURY II trial.
    Orvin K; Carrie D; Richardt G; Desmet W; Assali A; Werner G; Ikari Y; Fujii K; Goicolea J; Dangoisse V; Manari A; Saito S; Wijns W; Kornowski R
    Catheter Cardiovasc Interv; 2016 May; 87(6):1092-100. PubMed ID: 26268482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stents.
    Shah R
    Ann Intern Med; 2016 Dec; 165(11):828-829. PubMed ID: 27919089
    [No Abstract]   [Full Text] [Related]  

  • 12. Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stents.
    Zhang XL; Xu B
    Ann Intern Med; 2016 Dec; 165(11):829. PubMed ID: 27919088
    [No Abstract]   [Full Text] [Related]  

  • 13. Vascular response to bioresorbable polymer sirolimus-eluting stent vs. permanent polymer everolimus-eluting stent at 9-month follow-up: an optical coherence tomography sub-study from the CENTURY II trial.
    Kuramitsu S; Kazuno Y; Sonoda S; Domei T; Jinnouchi H; Yamaji K; Soga Y; Shirai S; Ando K; Saito S
    Eur Heart J Cardiovasc Imaging; 2016 Jan; 17(1):34-40. PubMed ID: 26333375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five-year outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease: final results from the ISAR-TEST 4 randomised trial.
    Kufner S; Byrne RA; Valeskini M; Schulz S; Ibrahim T; Hoppmann P; Schneider S; Laugwitz KL; Schunkert H; Kastrati A;
    EuroIntervention; 2016 Mar; 11(12):1372-9. PubMed ID: 25405657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of abluminal biodegradable polymer biolimus-eluting stents and durable polymer everolimus-eluting stents in the treatment of coronary bifurcations.
    Costopoulos C; Latib A; Naganuma T; Sticchi A; Ferrarello S; Regazzoli D; Chieffo A; Figini F; Carlino M; Montorfano M; Naim C; Kawaguchi M; Gerasimou A; Giannini F; Godino C; Colombo A
    Catheter Cardiovasc Interv; 2014 May; 83(6):889-95. PubMed ID: 23804318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-vitro mechanical behavior and in-vivo healing response of a new generation biodegradable polymer-coated thin-strut sirolimus-eluting stents.
    Gąsior P; Pyka Ł; Hawranek M; Garbacz M; Chagnon M; Beaudry D; Fluder J; Gąsior M; Wojakowski W; Lekston A
    Kardiol Pol; 2022; 80(1):72-75. PubMed ID: 34775590
    [No Abstract]   [Full Text] [Related]  

  • 17. A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial.
    de Winter RJ; Katagiri Y; Asano T; Milewski KP; Lurz P; Buszman P; Jessurun GAJ; Koch KT; Troquay RPT; Hamer BJB; Ophuis TO; Wöhrle J; Wyderka R; Cayla G; Hofma SH; Levesque S; Żurakowski A; Fischer D; Kośmider M; Goube P; Arkenbout EK; Noutsias M; Ferrari MW; Onuma Y; Wijns W; Serruys PW
    Lancet; 2018 Feb; 391(10119):431-440. PubMed ID: 29203070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparable vascular response of a new generation sirolimus eluting stents when compared to fluoropolymer everolimus eluting stents in the porcine coronary restenosis model.
    Buszman PP; Michalak MJ; Pruski M; Fernandez C; Jelonek M; Janas A; Savard C; Gwiazdowska-Nowotka B; Żurakowski A; Wojakowski W; Buszman PE; Milewski K
    Cardiol J; 2016; 23(6):657-666. PubMed ID: 27976797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized comparison of novel bioresorbable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent in patients with acute coronary syndromes: The CENTURY II high risk ACS substudy.
    Jiménez VA; Iñiguez A; Baz JA; Valdés M; Ortiz A; Vuilliomenet A; Mainar V; Dudek D; Banai S; Tüller D; Bonnet JL; De Miguel A; Bastos G; Wijns W; Saito S
    Cardiovasc Revasc Med; 2016 Sep; 17(6):355-61. PubMed ID: 27156201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the Absorbable Polymer Sirolimus-Eluting Stent (MiStent) to the Durable Polymer Everolimus-Eluting Stent (Xience) (from the DESSOLVE I/II and ISAR-TEST-4 Studies).
    Lansky AJ; Kastrati A; Edelman ER; Parise H; Ng VG; Ormiston J; Wijns W; Byrne RA
    Am J Cardiol; 2016 Feb; 117(4):532-538. PubMed ID: 26762729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.